Journal: Human Psychopharmacology

Article Title: Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia

doi: 10.1002/hup.2737

Figure Lengend Snippet: Frequencies of genotypes and alleles of ANKK1 rs2734849 in schizophrenia patients with and without HPRL ( n = 439)

Article Snippet: Genotyping for ANKK1 rs2734849 was carried out on the MassARRAY® Analyzer 4 (Agena BioscienceTM) using the set SEQUENOM Consumables iPLEX Gold 384.

Techniques:

Journal: Human Psychopharmacology

Article Title: Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia

doi: 10.1002/hup.2737

Figure Lengend Snippet: Frequencies of genotypes and alleles of ANKK1 rs2734849 in female schizophrenia patients with and without HPRL

Article Snippet: Genotyping for ANKK1 rs2734849 was carried out on the MassARRAY® Analyzer 4 (Agena BioscienceTM) using the set SEQUENOM Consumables iPLEX Gold 384.

Techniques:

Journal: Human Psychopharmacology

Article Title: Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia

doi: 10.1002/hup.2737

Figure Lengend Snippet: Frequencies of genotypes and alleles of ANKK1 rs2734849 in male schizophrenia patients with and without HPRL

Article Snippet: Genotyping for ANKK1 rs2734849 was carried out on the MassARRAY® Analyzer 4 (Agena BioscienceTM) using the set SEQUENOM Consumables iPLEX Gold 384.

Techniques:

Journal: Human Psychopharmacology

Article Title: Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia

doi: 10.1002/hup.2737

Figure Lengend Snippet: The distribution of prolactin levels depending on the ANKK1 rs2734849 genotypes in patients with schizophrenia, (ng/ml)

Article Snippet: Genotyping for ANKK1 rs2734849 was carried out on the MassARRAY® Analyzer 4 (Agena BioscienceTM) using the set SEQUENOM Consumables iPLEX Gold 384.

Techniques:

Journal: Human Psychopharmacology

Article Title: Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia

doi: 10.1002/hup.2737

Figure Lengend Snippet: Analysis of association between HPRL and ANKK1 rs2734849 in patients with schizophrenia from risperidone/paliperidone group ( n = 75)

Article Snippet: Genotyping for ANKK1 rs2734849 was carried out on the MassARRAY® Analyzer 4 (Agena BioscienceTM) using the set SEQUENOM Consumables iPLEX Gold 384.

Techniques:

Journal: medRxiv

Article Title: A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants

doi: 10.1101/2022.05.28.22275691

Figure Lengend Snippet: (A) SARS-CoV-2 genome with nucleotide positions from 5’-to-3’ direction depicted above. S gene polymorphisms targeted by the variant panel (lollipops) and corresponding amino acids are depicted below. (B) A color map depicts algorithms of target combinations that define 16 distinct SARS-CoV-2 variants on the panel. Variant results are depicted (left) which include the WHO designation (e.g., Omicron, Delta, etc.) and corresponding PANGO lineage assignments. Note that the B.1.526.1 variant was re-designated as B.1.637 to distinguish it from the Iota variant lineage ( https://cov-lineages.org/lineage_list.html , last accessed 4/26/22). The minimum number of targets required to support the corresponding variant result are indicated (right). Target results are depicted as colored cells indicating detectable native (e.g., unchanged from Wuhan-Hu-1 reference) amino acids which do not contribute to the variant target algorithm (grey), detectable native amino acids which do contribute to the algorithm (yellow), detectable amino acid polymorphisms (red), and dropout of the given target polymorphism. (C) Phylogenetic composition of 391 clinical specimen viral RNA recovered for diagnostic evaluation of the variant panel. Numbers of each lineage tested are depicted in brackets.

Article Snippet: We assessed the diagnostic performance of the highly multiplexed Agena MassARRAY ® SARS-CoV-2 Variant Panel v3 to identify variants in a diverse set of 391 SARS-CoV-2 clinical RNA specimens collected across our health systems in New York City, USA as well as in Bogotá, Colombia (September 2, 2020 – March 2, 2022).

Techniques: Variant Assay, Diagnostic Assay

Journal: medRxiv

Article Title: A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants

doi: 10.1101/2022.05.28.22275691

Figure Lengend Snippet: (A) A color map depicts the observed target results for three undefined SARS-CoV-2 variants tested on the panel: Lambda (C.37), Mu (B.1.621), and Omicron (BA.2). Distinct target patterns observed among each of the variant types are depicted. Cells indicate the distinct target results including detectable native amino acid (grey), detection of target polymorphism (red), and target dropout (green). The number of specimens that yielded each of the distinct target result patterns are indicated on the right as well as the output variant ID result generated by the variant panel software. (B) A heatmap depicts the measured prevalence of each variant panel target substitution among publicly-available Omicron sublineage genomes as of May 6, 2022.

Article Snippet: We assessed the diagnostic performance of the highly multiplexed Agena MassARRAY ® SARS-CoV-2 Variant Panel v3 to identify variants in a diverse set of 391 SARS-CoV-2 clinical RNA specimens collected across our health systems in New York City, USA as well as in Bogotá, Colombia (September 2, 2020 – March 2, 2022).

Techniques: Variant Assay, Generated, Software